Aurélie Fabre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aurélie Fabre has a total of 242 co-authors. Here are the top co-authors by number of shared publications:
- Sylviane Olschwang
INSERM, UMR1251, Marseille Med Genet Genet, Marseille, France
8 shared publications Philippe Grandval
Aix Marseille Univ, INSERM, GMGF, Marseille, France
4 shared publications- Christophe Béroud
INSERM U827, Laboratoire de Génétique Moleculaire, Montpellier, France
3 shared publications - Pascaline Gaildrat
Normandie Univ, UNIROUEN, Inserm U1245, Normandy Centre for Genomic and Personalized Medicine, F-76000 Rouen, France
3 shared publications Anthony Ferrari
2 shared publications- Arnaud Lagarde
AP-HM, Marseille, France
2 shared publications
Latest Publications
- 7 September 2016
- Published by Wiley in Human Mutation
- Vol. 37 (12) , 1299-1307
Actionable Genes, Core Databases, and Locus-Specific Databases
Adoption of next‐generation sequencing (NGS) in a diagnostic context raises numerous questions with regard to identification and reports of secondary variants (SVs) in actionable genes. To better understand the whys and wherefores of these questioning, it is necessary to understand how they are selected during the filtering process and how their proportion can be estimated. It is likely that SVs are underestimated and that our capacity to label all true SVs can be improved. In this context, Locus‐specific databases (LSDBs) can be key by providing a wealth of information and enabling classifying variants. We illustrate this issue by analyzing 318 SVs in 23 actionable genes involved in cancer susceptibility syndromes identified through sequencing of 572 participants selected for a range of atherosclerosis phenotypes. Among these 318 SVs, only 43.4% are reported in Human Gene Mutation Database (HGMD) Professional versus 71.4% in LSDB. In addition, 23.9% of HGMD Professional variants are reported as pathogenic versus 4.8% for LSDB. These data underline the benefits of LSDBs to annotate SVs and minimize overinterpretation of mutations thanks to their efficient curation process and collection of unpublished data.
- 7 September 2016
- Published by Wiley in Human Mutation
- Vol. 37 (12) , 1299-1307
Actionable Genes, Core Databases, and Locus-Specific Databases
Adoption of next‐generation sequencing (NGS) in a diagnostic context raises numerous questions with regard to identification and reports of secondary variants (SVs) in actionable genes. To better understand the whys and wherefores of these questioning, it is necessary to understand how they are selected during the filtering process and how their proportion can be estimated. It is likely that SVs are underestimated and that our capacity to label all true SVs can be improved. In this context, Locus‐specific databases (LSDBs) can be key by providing a wealth of information and enabling classifying variants. We illustrate this issue by analyzing 318 SVs in 23 actionable genes involved in cancer susceptibility syndromes identified through sequencing of 572 participants selected for a range of atherosclerosis phenotypes. Among these 318 SVs, only 43.4% are reported in Human Gene Mutation Database (HGMD) Professional versus 71.4% in LSDB. In addition, 23.9% of HGMD Professional variants are reported as pathogenic versus 4.8% for LSDB. These data underline the benefits of LSDBs to annotate SVs and minimize overinterpretation of mutations thanks to their efficient curation process and collection of unpublished data.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3534
Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial.
3534 Background: Bevacizumab (Bev) is widely used in mCRC but there is no validated predictive factor. Several studies have reported the impact of SNPs in the Vascular Endothelial Growth Factor-A (VEGF-A) pathway genes on the Bev’s efficacy but results in the mCRC are yet inconstant. PRODIGE 9 is a phase III trial that compare the tumor control duration (TCD) under a 1st-line chemotherapy followed by either Bev maintenance (Arm A) or no treatment during chemotherapy-free intervals (CFI) (Arm B).The aim of our study was to evaluate the impact of genetic polymorphisms of VEGF A, VEGFR1, VEGFR2 and HIF1α on TCD, duration of 1stCFI, progression-free survival (PFS) and overall survival (OS). Methods: We included patients (pts) of the PRODIGE 9 study for whom biological consent was signed and a DNA sample was available. Ten polymorphisms were genotyped on germ line DNA using real-time Polymerase Chain Reaction. DNA was extracted from blood samples. Survival analyses were done using Kaplan-Meier method and Cox model. For tRR, a logistic regression was used. Results: Among the 491 pts randomized in PRODIGE 9, DNA was available for 314 pts: 160 in Arm A and 154 in Arm B . The median TCD, OS and PFS, were respectively 15.7, 22.6 and 9.2 months (m). For VEGFR-1 rs9582036, pts with CC genotype had significantly better TCD (median [95%CI] 22.4 m [14.7- NR]) compared to pts with AA and CA genotypes (14.4 m [11.7-17.1] (p = 0.04)) in arm A whereas there was no difference in the other arm. This tendency was observed also for the 1st CFI (median 4.6 m for pts CC vs 4.1 m for AC and AA), for the median OS (28.2 vs 22.5 m), the RR, but it was not statistically significant (table). Conclusions: In this prospective study, VEGFR-1 rs9582036 variants were associated with clinical outcome in terms of TCD for patients with mCRC treated by Bev-based therapy. Clinical trial information: NCT00952029.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3534
Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial.
3534 Background: Bevacizumab (Bev) is widely used in mCRC but there is no validated predictive factor. Several studies have reported the impact of SNPs in the Vascular Endothelial Growth Factor-A (VEGF-A) pathway genes on the Bev’s efficacy but results in the mCRC are yet inconstant. PRODIGE 9 is a phase III trial that compare the tumor control duration (TCD) under a 1st-line chemotherapy followed by either Bev maintenance (Arm A) or no treatment during chemotherapy-free intervals (CFI) (Arm B).The aim of our study was to evaluate the impact of genetic polymorphisms of VEGF A, VEGFR1, VEGFR2 and HIF1α on TCD, duration of 1stCFI, progression-free survival (PFS) and overall survival (OS). Methods: We included patients (pts) of the PRODIGE 9 study for whom biological consent was signed and a DNA sample was available. Ten polymorphisms were genotyped on germ line DNA using real-time Polymerase Chain Reaction. DNA was extracted from blood samples. Survival analyses were done using Kaplan-Meier method and Cox model. For tRR, a logistic regression was used. Results: Among the 491 pts randomized in PRODIGE 9, DNA was available for 314 pts: 160 in Arm A and 154 in Arm B . The median TCD, OS and PFS, were respectively 15.7, 22.6 and 9.2 months (m). For VEGFR-1 rs9582036, pts with CC genotype had significantly better TCD (median [95%CI] 22.4 m [14.7- NR]) compared to pts with AA and CA genotypes (14.4 m [11.7-17.1] (p = 0.04)) in arm A whereas there was no difference in the other arm. This tendency was observed also for the 1st CFI (median 4.6 m for pts CC vs 4.1 m for AC and AA), for the median OS (28.2 vs 22.5 m), the RR, but it was not statistically significant (table). Conclusions: In this prospective study, VEGFR-1 rs9582036 variants were associated with clinical outcome in terms of TCD for patients with mCRC treated by Bev-based therapy. Clinical trial information: NCT00952029.
- Top Cited Papers
- 1 May 2016
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 98 (5) , 830-842
Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant
- 1 May 2016
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 98 (5) , 830-842
Top Cited PapersPoint Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant
- 23 April 2016
- Published by Springer Nature in Annals of Hematology
- Vol. 95 (7) , 1043-1050
Mutational analysis of JAK2, CBL, RUNX1, and NPM1 genes in familial aggregation of hematological malignancies
Familial aggregation of hematological malignancies has been reported highlighting inherited genetic predisposition. In this study, we targeted four candidate genes: JAK2 and RUNX1 genes assuring a prominent function in hematological process and CBL and NPM1 as proto-oncogenes. Their disruption was described in several sporadic hematological malignancies. The aim of this study is to determine whether JAK2, CBL, RUNX1, and NPM1 germline genes mutations are involved in familial hematological malignancies. Using direct sequencing, we analyzed JAK2 (exons 12 and 14); CBL (exons 7, 8 and 9); NPM1 (exon 12) and the entire RUNX1 in 88 independent families belonging to Tunisian and French populations. Twenty-one sporadic acute leukemias were included in this study. We reported a heterozygous intronic c.1641 + 6 T > C JAK2 variant (rs182123615) found in two independent familial cases diagnosed with gastric lymphoma and Hodgkin lymphoma. The in silico analysis suggested a potential impact on splicing, but the functional splicing minigene reporter assay on rs182123615 variant showed no aberrant transcripts. In one sporadic acute myeloblastic leukemia, we reported an insertion 846 in. TGTT in exon 12 of NPM1 gene that may impact the normal reading frame. The rs182123615 JAK2 variant was described in several contexts including myeloproliferative neoplasms and congenital erythrocytosis and was supposed to be pathogenic. Through this current study, we established the assessment of pathogenicity of rs182123615 and we classified it rather as rare polymorphism.
- 23 April 2016
- Published by Springer Nature in Annals of Hematology
- Vol. 95 (7) , 1043-1050
Mutational analysis of JAK2, CBL, RUNX1, and NPM1 genes in familial aggregation of hematological malignancies
Familial aggregation of hematological malignancies has been reported highlighting inherited genetic predisposition. In this study, we targeted four candidate genes: JAK2 and RUNX1 genes assuring a prominent function in hematological process and CBL and NPM1 as proto-oncogenes. Their disruption was described in several sporadic hematological malignancies. The aim of this study is to determine whether JAK2, CBL, RUNX1, and NPM1 germline genes mutations are involved in familial hematological malignancies. Using direct sequencing, we analyzed JAK2 (exons 12 and 14); CBL (exons 7, 8 and 9); NPM1 (exon 12) and the entire RUNX1 in 88 independent families belonging to Tunisian and French populations. Twenty-one sporadic acute leukemias were included in this study. We reported a heterozygous intronic c.1641 + 6 T > C JAK2 variant (rs182123615) found in two independent familial cases diagnosed with gastric lymphoma and Hodgkin lymphoma. The in silico analysis suggested a potential impact on splicing, but the functional splicing minigene reporter assay on rs182123615 variant showed no aberrant transcripts. In one sporadic acute myeloblastic leukemia, we reported an insertion 846 in. TGTT in exon 12 of NPM1 gene that may impact the normal reading frame. The rs182123615 JAK2 variant was described in several contexts including myeloproliferative neoplasms and congenital erythrocytosis and was supposed to be pathogenic. Through this current study, we established the assessment of pathogenicity of rs182123615 and we classified it rather as rare polymorphism.
- 6 October 2015
- Published by Wiley in Clinical Genetics
- Vol. 89 (2) , 267-268
Consideration surrounding incidental findings throughout multigene panel testing in cancer genetics
- 6 October 2015
- Published by Wiley in Clinical Genetics
- Vol. 89 (2) , 267-268
Consideration surrounding incidental findings throughout multigene panel testing in cancer genetics
- 19 August 2015
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 18 (4) , 385-390
Familial hematological malignancies: ASXL1 gene investigation
- 19 August 2015
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 18 (4) , 385-390
Familial hematological malignancies: ASXL1 gene investigation
- 1 April 2015
- Published by Elsevier in Digestive and Liver Disease
- Vol. 47 (4) , 331-337
Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer
- 1 April 2015
- Published by Elsevier in Digestive and Liver Disease
- Vol. 47 (4) , 331-337
Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer
- 3 November 2014
- Published by BMJ in Journal of Medical Genetics
- Vol. 52 (1) , 25-27
Genomic variations integrated database for MUTYH-associated adenomatous polyposis
- 3 November 2014
- Published by BMJ in Journal of Medical Genetics
- Vol. 52 (1) , 25-27
Genomic variations integrated database for MUTYH-associated adenomatous polyposis
- Open Access
- 5 August 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 1-9
Constitutive AKT activation in follicular lymphoma
- 5 August 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 1-9
Open AccessConstitutive AKT activation in follicular lymphoma
- Top Cited PapersOpen Access
- 22 December 2013
- Published by Springer Nature in Nature Genetics
- Vol. 46 (2) , 107-115
Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database
Community microattribution review of the evidence for colon cancer risk conferred by constitutional variants in MLH1, MSH2, MSH6 and PMS2 has resulted in the reclassification of two-thirds of the variants reported in existing databases and led to clinical recommendations for the interpretation of 1,370 variants that do not result in obvious protein truncation. The clinical classification of hereditary sequence variants identified in disease-related genes directly affects clinical management of patients and their relatives. The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) undertook a collaborative effort to develop, test and apply a standardized classification scheme to constitutional variants in the Lynch syndrome–associated genes MLH1, MSH2, MSH6 and PMS2. Unpublished data submission was encouraged to assist in variant classification and was recognized through microattribution. The scheme was refined by multidisciplinary expert committee review of the clinical and functional data available for variants, applied to 2,360 sequence alterations, and disseminated online. Assessment using validated criteria altered classifications for 66% of 12,006 database entries. Clinical recommendations based on transparent evaluation are now possible for 1,370 variants that were not obviously protein truncating from nomenclature. This large-scale endeavor will facilitate the consistent management of families suspected to have Lynch syndrome and demonstrates the value of multidisciplinary collaboration in the curation and classification of variants in public locus-specific databases.
- 22 December 2013
- Published by Springer Nature in Nature Genetics
- Vol. 46 (2) , 107-115
Top Cited PapersOpen AccessApplication of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database
Community microattribution review of the evidence for colon cancer risk conferred by constitutional variants in MLH1, MSH2, MSH6 and PMS2 has resulted in the reclassification of two-thirds of the variants reported in existing databases and led to clinical recommendations for the interpretation of 1,370 variants that do not result in obvious protein truncation. The clinical classification of hereditary sequence variants identified in disease-related genes directly affects clinical management of patients and their relatives. The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) undertook a collaborative effort to develop, test and apply a standardized classification scheme to constitutional variants in the Lynch syndrome–associated genes MLH1, MSH2, MSH6 and PMS2. Unpublished data submission was encouraged to assist in variant classification and was recognized through microattribution. The scheme was refined by multidisciplinary expert committee review of the clinical and functional data available for variants, applied to 2,360 sequence alterations, and disseminated online. Assessment using validated criteria altered classifications for 66% of 12,006 database entries. Clinical recommendations based on transparent evaluation are now possible for 1,370 variants that were not obviously protein truncating from nomenclature. This large-scale endeavor will facilitate the consistent management of families suspected to have Lynch syndrome and demonstrates the value of multidisciplinary collaboration in the curation and classification of variants in public locus-specific databases.